Dongni Johansson1, Anders Ericsson2, Anders Johansson3, Alexander Medvedev4, Dag Nyholm5, Fredrik Ohlsson2, Marina Senek5, Jack Spira6, Ilias Thomas7, Jerker Westin7, Filip Bergquist1,8. 1. Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. RISE Acreo AB, Gothenburg, Sweden. 3. Department of Clinical Neuroscience, Neurology, Karolinska Institutet, Stockholm, Sweden. 4. Department of Information Technology, Uppsala University, Uppsala, Sweden. 5. Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden. 6. Sensidose AB, Sollentuna, Sweden. 7. Computer Engineering, Dalarna University, Falun, Sweden. 8. Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Abstract
AIM: This 4-week open-label observational study describes the effect of introducing a microtablet dose dispenser and adjusting doses based on objective free-living motor symptom monitoring in individuals with Parkinson's disease (PD). METHODS: Twenty-eight outpatients with PD on stable levodopa treatment with dose intervals of ≤4 hour had their daytime doses of levodopa replaced with levodopa/carbidopa microtablets, 5/1.25 mg (LC-5) delivered from a dose dispenser device with programmable reminders. After 2 weeks, doses were adjusted based on ambulatory accelerometry and clinical monitoring. RESULTS: Twenty-four participants completed the study per protocol. The daily levodopa dose was increased by 15% (112 mg, P < 0.001) from period 1 to 2, and the dose interval was reduced by 12% (22 minutes, P = 0.003). The treatment adherence to LC-5 was high in both periods. The MDS-UPDRS parts II and III, disease-specific quality of life (PDQ-8), wearing-off symptoms (WOQ-19), and nonmotor symptoms (NMS Quest) improved after dose titration, but the generic quality-of-life measure EQ-5D-5L did not. Blinded expert evaluation of accelerometry results demonstrated improvement in 60% of subjects and worsening in 25%. CONCLUSIONS: The introduction of a levodopa microtablet dispenser and accelerometry aided dose adjustments improve PD symptoms and quality of life in the short term.
AIM: This 4-week open-label observational study describes the effect of introducing a microtablet dose dispenser and adjusting doses based on objective free-living motor symptom monitoring in individuals with Parkinson's disease (PD). METHODS: Twenty-eight outpatients with PD on stable levodopa treatment with dose intervals of ≤4 hour had their daytime doses of levodopa replaced with levodopa/carbidopa microtablets, 5/1.25 mg (LC-5) delivered from a dose dispenser device with programmable reminders. After 2 weeks, doses were adjusted based on ambulatory accelerometry and clinical monitoring. RESULTS: Twenty-four participants completed the study per protocol. The daily levodopa dose was increased by 15% (112 mg, P < 0.001) from period 1 to 2, and the dose interval was reduced by 12% (22 minutes, P = 0.003). The treatment adherence to LC-5 was high in both periods. The MDS-UPDRS parts II and III, disease-specific quality of life (PDQ-8), wearing-off symptoms (WOQ-19), and nonmotor symptoms (NMS Quest) improved after dose titration, but the generic quality-of-life measure EQ-5D-5L did not. Blinded expert evaluation of accelerometry results demonstrated improvement in 60% of subjects and worsening in 25%. CONCLUSIONS: The introduction of a levodopa microtablet dispenser and accelerometry aided dose adjustments improve PD symptoms and quality of life in the short term.
Authors: Kallol Ray Chaudhuri; Pablo Martinez-Martin; Anthony H V Schapira; Fabrizio Stocchi; Kapil Sethi; Per Odin; Richard G Brown; William Koller; Paolo Barone; Graeme MacPhee; Linda Kelly; Martin Rabey; Doug MacMahon; Sue Thomas; William Ondo; David Rye; Alison Forbes; Susanne Tluk; Vandana Dhawan; Annette Bowron; Adrian J Williams; Charles W Olanow Journal: Mov Disord Date: 2006-07 Impact factor: 10.338
Authors: M Reuther; E A Spottke; J Klotsche; O Riedel; H Peter; K Berger; O Athen; R Köhne-Volland; R C Dodel Journal: Parkinsonism Relat Disord Date: 2006-10-19 Impact factor: 4.891
Authors: Richard Gray; Natalie Ives; Caroline Rick; Smitaa Patel; Alastair Gray; Crispin Jenkinson; Emma McIntosh; Keith Wheatley; Adrian Williams; Carl E Clarke Journal: Lancet Date: 2014-06-11 Impact factor: 79.321
Authors: Dongni Johansson; Anders Ericsson; Anders Johansson; Alexander Medvedev; Dag Nyholm; Fredrik Ohlsson; Marina Senek; Jack Spira; Ilias Thomas; Jerker Westin; Filip Bergquist Journal: CNS Neurosci Ther Date: 2018-01-25 Impact factor: 5.243
Authors: Gökçe Kilinçalp; Anne-Christine Sjöström; Barbro Eriksson; Björn Holmberg; Radu Constantinescu; Filip Bergquist Journal: J Pers Med Date: 2022-01-02